These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
35. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807 [TBL] [Abstract][Full Text] [Related]
36. Fluid biomarkers in Alzheimer's disease - current concepts. Rosén C; Hansson O; Blennow K; Zetterberg H Mol Neurodegener; 2013 Jun; 8():20. PubMed ID: 23800368 [TBL] [Abstract][Full Text] [Related]
37. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669 [TBL] [Abstract][Full Text] [Related]
38. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397 [TBL] [Abstract][Full Text] [Related]
39. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O; Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649 [TBL] [Abstract][Full Text] [Related]
40. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Welge V; Fiege O; Lewczuk P; Mollenhauer B; Esselmann H; Klafki HW; Wolf S; Trenkwalder C; Otto M; Kornhuber J; Wiltfang J; Bibl M J Neural Transm (Vienna); 2009 Feb; 116(2):203-12. PubMed ID: 19142572 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]